- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Adjuvant and Neoadjuvant Treatments for Resectable Hepatocellular Carcinoma ; volume:25 ; number:10 ; day:9 ; month:9 ; year:2023 ; pages:1191-1201 ; date:10.2023
Current oncology reports ; 25, Heft 10 (9.9.2023), 1191-1201, 10.2023
- Creator
-
Crook, Christiana J.
Li, Daneng
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s11912-023-01455-9
- URN
-
urn:nbn:de:101:1-2023122722582781400566
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:26 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Crook, Christiana J.
- Li, Daneng
- SpringerLink (Online service)
Other Objects (12)
Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC
Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a clinical practice guideline
Neoadjuvant versus adjuvant management of resectable pancreas cancer: A review of the literature
Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial
Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma?
Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis
Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial
Analysis of early postoperative complications in patients with resectable rectal cancer after neo-adjuvant chemo-radiotherapy
CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial
Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC
Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a clinical practice guideline
Neoadjuvant versus adjuvant management of resectable pancreas cancer: A review of the literature
Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial
Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma?
Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis
Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial
Analysis of early postoperative complications in patients with resectable rectal cancer after neo-adjuvant chemo-radiotherapy
CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial
Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC
Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a clinical practice guideline
Neoadjuvant versus adjuvant management of resectable pancreas cancer: A review of the literature
Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial
Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma?
Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis
Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial
Analysis of early postoperative complications in patients with resectable rectal cancer after neo-adjuvant chemo-radiotherapy
CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)